Commodore Capital

Early clinical data show efficacy signals that appear to improve on existing therapies in GI cancer settings

In BioCentury’s Finance Report: Travere’s follow-on, CrossBridge’s seed round among few fundings during quiet election week

Plus: Financings for newcos Nilo, Jade, Red Queen

Plus: A PIPE for CervoMed ahead of dementia readout; and Stoke, Praxis follow clinical readouts with opportunistic follow-ons

Plus: LianBio begins winding down, promises dividend; BioXcel pulls offering

Plus: FDA guidance facilitates communication about off-label uses and updates from Verve, Celltrion, Sanofi, Regeneron, Revolution, Harpoon, Aligos

Plus: Novartis’ iptacopan shows benefit in IgA nephropathy and updates from Mirum, Lexeo, Rocket, Lilly, Syndax, SAB, Amicus and Pneumagen

Plus: Venture cash for ADARx, Georgiamune, Neurophth and updates from Regeneron-Decibel, Novartis, Sunbird-Glympse, Denali-Takeda and more

Plus: Tourmaline reverse-merging with Talaris, CAR T shows early efficacy in myasthenia gravis, and updates from AltPep, Solve and Intercept

Plus: Siren, Sania debut and updates from Aitia, PTC, enGene, Ardelyx, Akero and Satellos